Radequinil

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Radequinil
Radequinil.svg
Systematic (IUPAC) name
5-(3-methoxyphenyl)-3-(5-methyl-1,2,4-oxadiazol-3-yl)-1,6-naphthyridin-2(1H)-one
Clinical data
Legal status
?
Identifiers
CAS number 219846-31-8
ATC code None
PubChem CID 22714308
ChemSpider 11584471
Chemical data
Formula C18H14N4O3 
Mol. mass 334.329 g/mol

Radequinil (INN; AC-3933) is a cognitive enhancer which acts as a partial inverse agonist of the benzodiazepine site of the GABAA receptor.[1] It was under development by Dainippon Sumitomo Pharma for the treatment of Alzheimer's disease and made it to phase II clinical trials but development seems to have been halted and it was never marketed.[1][2]

See also[edit]

References[edit]

  1. ^ a b Martocchia A, Falaschi P (2008). "Current Strategies of Therapy in Alzheimer’s Disease". The Open Neuropsychopharmacology Journal 1: 19–23. 
  2. ^ Pogacic, Vanda; Herling, Paul (2007). "List of Drugs in Development for Neurodegenerative Diseases". Neurodegenerative Diseases 4 (6): 443486. doi:10.1159/000107705. ISSN 1660-2862.